Hummingbird migrates ADCs, tech to newco Callio’s $187M debut March 4, 2025 By Marian (YoonJee) Chu Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug technology and assets in-licensed from Hummingbird Bioscience Pte Ltd.Read More
